Label-free screening of drug-induced liver injury using stimulated Raman scattering microscopy and spectral phasor analysis

Tools

Tipping, William J. and Wilson, Liam T. and Tomkinson, Nicholas C. O. and Faulds, Karen and Graham, Duncan (2024) Label-free screening of drug-induced liver injury using stimulated Raman scattering microscopy and spectral phasor analysis. Analytical Chemistry, 96 (26). pp. 10639-10647. ISSN 0003-2700 (https://doi.org/10.1021/acs.analchem.4c01285)

[thumbnail of Tipping-eatl-AC-2024-Label-free-screening-of-drug-induced-liver-injury]
Preview
 Text. Filename: Tipping-eatl-AC-2024-Label-free-screening-of-drug-induced-liver-injury.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (4MB)| Preview

Abstract

Hepatic toxicity is a leading cause of the termination of clinical trials and the withdrawal of therapeutics following regulatory approval. The detection of drug-induced liver injury (DILI) is therefore of importance to ensure patient safety and the effectiveness of novel small molecules and drugs. DILI encompasses drug-induced steatosis (DIS) and drug-induced phospholipidosis (DIPL) which involve the accumulation of excess intracellular lipids. Here, we develop hyperspectral stimulated Raman scattering (SRS) microscopy as a label-free methodology for discriminating DIS and DIPL in mammalian cell culture. We demonstrate that hyperspectral SRS imaging in tandem with spectral phasor analysis is capable of discriminating DIS and DIPL based on the nature and distribution of intracellular lipids resulting from each process. To demonstrate the practical application of this methodology, we develop a panel of alkyne-tagged propranolol analogues that display varying DILI effects. Using hyperspectral SRS imaging together with spectral phasor analysis, our label-free methodology corroborated the standard fluorescence-based assay for DILI. As a label-free screening method, it offers a convenient and expedient methodology for visualizing hepatotoxicity in cell cultures which could be integrated into the early stages of the drug development process for screening new chemical entities for DILI.

ORCID iDs

Tipping, William J., Wilson, Liam T., Tomkinson, Nicholas C. O. ORCID logoORCID: https://orcid.org/0000-0002-5509-0133, Faulds, Karen ORCID logoORCID: https://orcid.org/0000-0002-5567-7399 and Graham, Duncan ORCID logoORCID: https://orcid.org/0000-0002-6079-2105;
CORE (COnnecting REpositories)